ARISTO

Aristo Bio-Tech and Lifescience Share Price

₹105.00 0.00 (0.00%)

22 Feb, 2025 22:01

SIP TrendupStart SIP in ARISTO

Start SIP

Performance

  • Low
  • ₹105
  • High
  • ₹105
  • 52 Week Low
  • ₹53
  • 52 Week High
  • ₹164
  • Open Price₹105
  • Previous Close₹105
  • Volume1,600

Investment Returns

  • Over 1 Month -18.67%
  • Over 3 Month -30.67%
  • Over 6 Month -0.19%
  • Over 1 Year + 22.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Aristo Bio-Tech and Lifescience for Steady Growth!

Invest Now

Aristo Bio-Tech and Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 18.3
  • PEG Ratio
  • -
  • Market Cap Cr
  • 72
  • P/B Ratio
  • 2.1
  • Average True Range
  • 7
  • EPS
  • 5.72
  • Dividend Yield
  • 0
  • MACD Signal
  • -5.83
  • RSI
  • 35.06
  • MFI
  • 63.3

Aristo Bio-Tech and Lifescience Financials

Aristo Bio-Tech and Lifescience Technicals

EMA & SMA

Current Price
₹105.00
0 (0%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹121.69
  • 50 Day
  • ₹128.50
  • 100 Day
  • ₹124.34
  • 200 Day
  • ₹111.82

Resistance and Support

105 Pivot Speed
  • R3 105.00
  • R2 105.00
  • R1 105.00
  • S1 105.00
  • S2 105.00
  • S3 105.00

What's your outlook on Aristo Bio-Tech and Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Aristo Bio-Tech And Lifescience has an operating revenue of Rs. 809.98 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 2% needs improvement, ROE of 11% is good. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 80 indicates it belongs to a poor industry group of Chemicals-Agricultural and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aristo Bio-Tech and Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results & Others To consider other business matters.
2024-05-27 Audited Results & Dividend
2023-11-07 Quarterly Results
2023-05-27 Audited Results & Dividend
Date Purpose Remarks
2023-09-15 FINAL Recommended Final Dividend of 0.25 per equity share
View More

Aristo Bio-Tech and Lifescience F&O

Aristo Bio-Tech and Lifescience Shareholding Pattern

73.37%
23.69%
2.94%

About Aristo Bio-Tech and Lifescience

  • NSE Symbol
  • ARISTO
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Narendra Singh Barhat
  • ISIN
  • INE082101010

Similar Stocks to Aristo Bio-Tech and Lifescience

Aristo Bio-Tech and Lifescience FAQs

Aristo Bio-Tech and Lifescience share price is ₹105 As on 22 February, 2025 | 21:47

The Market Cap of Aristo Bio-Tech and Lifescience is ₹71.5 Cr As on 22 February, 2025 | 21:47

The P/E ratio of Aristo Bio-Tech and Lifescience is 18.3 As on 22 February, 2025 | 21:47

The PB ratio of Aristo Bio-Tech and Lifescience is 2.1 As on 22 February, 2025 | 21:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23